Plain-English translation of NCT06492798 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing mesenchymal stem cell therapy — a treatment using special cells from the body that can reduce inflammation and help healing — for people with long COVID. Long COVID is a condition where symptoms like fatigue, breathing difficulties, muscle pain, and sleep problems persist for months after a COVID-19 infection. The study will give some participants the stem cell treatment and others a placebo (inactive infusion) to see if the treatment is safe and helps people feel better.
Most people who recover from COVID-19 still experience long-term symptoms that affect their quality of life, and there are currently no proven medical treatments specifically designed to help. This trial exists to see whether this medication might reduce inflammation in the body and help people with long COVID recover.
If you join this trial, you will receive either one or two intravenous infusions (injections into a vein) of the stem cell treatment or a placebo, with a possible second infusion given 5–6 weeks after the first if your doctor recommends it. You will be monitored to make sure the treatment is safe and to track whether your long COVID symptoms improve over time. The study involves 76 participants total, and researchers at Changhai Hospital are currently recruiting people to join.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China